Angiotensin Receptor Blockers (ARBs) Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Angiotensin Receptor Blockers (ARBs) Market Size Changed, over the years?
The market size for angiotensin receptor blockers (ARBs) has seen consistent growth in the past few years. The market is expected to increase from $8.51 billion in 2024 to $8.87 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.1%. Factors such as the widespread prevalence of hypertension, clinical effectiveness, the high burden of cardiovascular disease, renal protective qualities, established clinical guidelines, the positioning of ARBs as a first-line treatment, and cost-effectiveness have contributed to the growth during the historical period.
How Much Will the Angiotensin Receptor Blockers (ARBs) Market Be Worth in 2029?
In the coming years, the market size for Angiotensin receptor blockers (ARBs) is projected to experience a steady growth, eventually reaching approximately $10.76 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The expected growth within the forecast period can be ascribed to the adoption of precision medicine approaches, emphasis on combination therapies, global market expansion, biomarker-centric treatment tactics, government initiatives, and a heightened awareness of hypertension. Within the forecast period, significant trends are anticipated to include the adoption of telemedicine, investment in research and development, generic competition accompanied by patent expirations, tech-driven solutions for medication adherence, and competition from biosimilars.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
Which is the Largest Company in the Angiotensin Receptor Blockers (ARBs) Market?
Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma
What Are the Main Market Drivers in the Angiotensin Receptor Blockers (ARBs) Industry?
The surge in cardiovascular diseases is anticipated to boost the expansion of the angiotensin receptor blockers market. Cardiovascular disease, which affects the heart or blood vessels, commonly involves the buildup of fatty deposits in the arteries, also known as atherosclerosis, leading to a heightened risk of blood clots. Angiotensin receptor blockers, which aid in the relaxation of veins and arteries, have been found to lower blood pressure and enhance the heart’s blood pumping ability, thereby reducing the risk of cardiovascular disease. In a forecast by the American College of Cardiology, a professional medical organization based in the US, in August 2022, it was revealed that the incidence of cardiovascular risk factors and disease in the United States is set to rise significantly by 2060. Consequently, the escalating prevalence of cardiovascular diseases is fuelling the growth of the angiotensin receptor blockers market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp
How Is the Angiotensin Receptor Blockers (ARBs) Market Segments Structured?
The angiotensin receptor blockers (ARBs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension
What Strategic Trends Are Transforming the Angiotensin Receptor Blockers (ARBs) Market?
Leading players in the angiotensin receptor blocker market are forging ahead with innovative products such as angiotensin receptor neprilysin inhibitors. These new developments aim to broaden treatment alternatives and yield better results for patients coping with cardiovascular illnesses. Angiotensin receptor neprilysin inhibitors (ARNIs) stand as a vital medication subset for the treatment of heart failure. For example, in January 2023, sacubitril + valsartan tablets were introduced into the market by Glenmark Pharmaceuticals, a firm based in India, targeting specifically heart failure with reduced ejection fraction (HFrEF). This combination belongs to ARNI, a lineup of medications known for this action. Sacubitril boosts the natriuretic peptide (NP) system, leading to fluid overload reduction and enhanced blood vessel dilation, whereas valsartan restricts the renin-angiotensin system (RAS), decreasing both blood pressure and the heart’s work output. When combined, they provide an effective mitigation strategy for heart failure symptoms, a lowered cardiovascular death risk, and a decrease in hospitalization due to heart failure. These tablets are sold under the brand Sacu V.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Angiotensin Receptor Blockers (ARBs) Market?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943
This Report Delivers Insight On:
1. How big is the angiotensin receptor blockers (arbs) market, and how is it changing globally?
2. Who are the major companies in the angiotensin receptor blockers (arbs) market, and how are they performing?
3. What are the key opportunities and risks in the angiotensin receptor blockers (arbs) market right now?
4. Which products or customer segments are growing the most in the angiotensin receptor blockers (arbs) market?
5. What factors are helping or slowing down the growth of the angiotensin receptor blockers (arbs) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
